JPRN-UMIN000008839已完成2 期
Randomized phase II study of eribulin versus nab-paclitaxel in patients with relapsed HER2-negative breast cancer previously treated with anthracycline and peri-operative taxane - EVA study
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) prior eribulin and/or nab-paclitaxel 2) taxane for metastatic disease 3) <6monthd from last taxane administration 4) Effusions (pleural, pericardial effusion, ascites) requiring treatment 5) brain metastasis requiring treatment 6) >=grade 2 peripheral sensory neuropathy (CTCAE ver4.0) 7) clinically abnormal ECG 8) systemic infection 9) severe diabetes mellitus 10) interstitial pneumonia/pulmonary fibrosis apparent on chest Xp 11) active double cancer 12) severe psychosis 13) systemic corticosteroid 14) severe drug allergy 15) hypersensitivity for paclitaxel and/or albumin 16) positive HBs antigen 17) pregnant or lactating woman 18) other causes judged ineligible by attending physician
研究者
相似试验
已完成
2 期
A phase 2 study of eribulin in combination with pertuzumab and trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancerJPRN-UMIN000014107SONG (South Osaka Network Group for Breast Cancer)43
招募中
2 期
Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer.Advanced/recurrent HER2-positive breast cancerJPRN-UMIN000011020Sairtama Breast Cancer Clinical Study Group (SBCCSG)na35
进行中（未招募）
1 期
A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic canceradvanced pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2017-003621-15-ITAZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA25
已完成
2 期
A phase II study of eribulin in combination with trastuzumab and pertuzumab as First-Line therapy for metastatic HER2-positive breast cancerFirst-Line therapy for metastatic HER2-positive breast cancer.JPRN-UMIN000021585Sairtama Breast Cancer Clinical Study Group (SBCCSG)16
已完成
2 期
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who presented well-defined taxane resistanceBreast CancerJPRN-UMIN000006965Saitama Breast Cancer Clinical Study Group (SBCCSG)52